Solid Biosciences (SLDB) Net Cash Flow Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 453.08% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -125.22% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 53.46% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 81.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.39% |
| Dec 31, 2025 | -108.81% |
| Sep 30, 2025 | -146.73% |
| Jun 30, 2025 | -231.49% |
| Mar 31, 2025 | 199.40% |
| Dec 31, 2024 | -36.50% |
| Sep 30, 2024 | 26.08% |
| Jun 30, 2024 | 71.41% |
| Mar 31, 2024 | 370.15% |
| Dec 31, 2023 | -76.51% |
| Sep 30, 2023 | -670.37% |
| Jun 30, 2023 | -0.39% |
| Mar 31, 2023 | -12.39% |
| Dec 31, 2022 | 1,035.32% |
| Sep 30, 2022 | 93.93% |
| Jun 30, 2022 | -14.15% |
| Mar 31, 2022 | -90.70% |
| Dec 31, 2021 | 651.24% |
| Sep 30, 2021 | -481.25% |
| Jun 30, 2021 | -418.24% |
| Mar 31, 2021 | 597.69% |
| Dec 31, 2020 | 106.68% |
| Sep 30, 2020 | -2.40% |
| Jun 30, 2020 | -490.64% |
| Mar 31, 2020 | 29.40% |
| Dec 31, 2019 | 56.24% |
| Sep 30, 2019 | 8.44% |
| Jun 30, 2019 | 88.65% |
| Mar 31, 2019 | -128.67% |
| Dec 31, 2018 | -215.46% |
| Sep 30, 2018 | 5.71% |
| Jun 30, 2018 | -651.77% |
| Mar 31, 2018 | 423.11% |